Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2022-12-23

Molecular Targeting of Leukaemic Differentiation Therapy Using Acute Promyelocytic Leukaemia as Model

Objective



Balanced dNTP pool sizes are prerequisites for controlled cell proliferation, any disturbance causes mutations and cell transformation. Mammalian cells have to adapt rapidly to their microenvironment, especially during cell differentiation. This might be the reason why the nucleoside salvage has a vital importance during lymphocyte differentiation. If cells cannot salvage purine nucleosides (ADA and PNP deficiencies) severe immunodeficiencis are developing (SCIOS), however their molecular mechanisms are still not clear (Van Learhoven 1983, Reichard 1989). Deoxycytidilate Deaminase is one of the most important enzyme inthe regulation of nucleotide pools, which is modulating not only the native nucleotide concentrations but also the concentrations of the active metabolites of anticancer and cell-differentiating drugs. The function of this well regulated enzyme is essential in the action of the anti-leucaemic drug 2-Cl-dADO, as well in development of new nucleoside analogues. Intracellular activation of CdA leads to formation of 2-Cl-dAMP and to 2-Cl-dATP. 2-Cl-dATP is known to inhibit ribonucleotide reductase. However, there are contradictions in the literature regarding the active intracellular intermedier and the target enzyme of this very important antileucaemic agent. Preliminary data, found in the laboratory of the proposer show that the active interme of CdA is rather 2-Cl-AMP than 2-Cl-ATP, so the proposer suggest a new target enzyme in the action of this drug: deoxycytidylat deaminase (dCMP-deaminase). dCMP-deaminase is a new target enzyme in anticancer and antiviral therapy, like in treatment of hepatitis with 2,3-dideoxycytidine, or in treatment with 2,2-difluorodeoxycytidine. In the proposal, the exact mode of CdA inhibition will be investigated in human lymphocytes including the investigation of several subpopulations at various level of differentiation, as well as in other lymphoma cell lines.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

Data not available

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CSC - Cost-sharing contracts

Coordinator

ASSOCIATION CLAUDE BERNARD
EU contribution
No data
Address
Rue Scipion, 13
75005 PARIS
France

See on map

Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (1)

My booklet 0 0